Corcept Therapeutics Inc (CORT) company profile

The company is a commercial-stage biopharmaceutical organization focused on discovering and developing treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its core scientific approach involves modulating cortisol activity using proprietary compounds that target the glucocorticoid receptor. The company markets Korlym and an authorized generic mifepristone product in the United States to treat patients diagnosed with hypercortisolism, or Cushing’s syndrome. In addition to commercial therapies, its research pipeline includes investigational selective modulators such as relacorilant for endocrine disorders and solid tumors, miricorilant for metabolic dysfunction-associated steatohepatitis, and dazucorilant for amyotrophic lateral sclerosis. The primary customers are patients prescribed these therapies through physicians and specialized pharmacy channels.

Commercial operations and product distribution are centered in the United States, utilizing internal field sales forces, medical science liaisons, and designated specialty pharmacy networks. Development activities, regulatory submissions, and clinical trials span both the United States and the European Union, with international patent holdings covering major markets. The provided text contains no mention of the company's headquarters location.

Summary of the business section of Corcept Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of December 31, 2025, we had 730 employees.”